SCI
31May
ControlledTrialofBudesonide–FormoterolasNeededforMildAsthma
BeasleyR,HollidayM,ReddelHK,etal.ControlledTrialofBudesonide-FormoterolasNeededforMildAsthma.NEnglJMed;:-30.
AddressreprintrequeststoDr.BeasleyattheMedicalResearchInstituteofNewZealand,PrivateBag,Newtown,Wellington,NewZealand,oratrichard.beasley
mrinz.ac.nz.BACKGROUND背景
Indouble-blind,placebo-controlledtrials,budesonide–formoterolusedonanasneededbasisresultedinalowerriskofsevereexacerbationofasthmathanas-neededuseofashort-actingβ2-agonist(SABA);theriskwassimilartothatofbudesonidemaintenancetherapyplusas-neededSABA.Theavailabilityofdatafromclinicaltrialsdesignedtobetterreflectclinicalpracticewouldbebeneficial.
在以往的双盲,安慰剂对照试验中,在必要的基础上使布地奈德-福莫特罗相对于使用短效β2-受体激动剂(SABA)可更加降低哮喘严重恶化的风险;该风险与布地奈德维持治疗加发作时使用SABA治疗的恶化风险相似。临床试验能更好地反映临床实践，其所得出的数据很有意义。
METHODS方法
Weconducteda52-week,randomized,open-label,parallel-group,controlledtrialinvolvingadultswithmildasthma.Patientswererandomlyassignedtooneofthreetreatmentgroups:albuterol(μg,twoinhalationsfromapressurizedmetereddoseinhalerasneededforasthmasymptoms)(albuterolgroup);budesonide(μg,oneinhalationthroughaTurbuhalertwicedaily)plusas-neededalbuterol(budesonidemaintenancegroup);orbudesonide–formoterol(μgofbudesonideand6μgofformoterol,oneinhalationthroughaTurbuhalerasneeded)(budesonide–formoterolgroup).Electronicmonitoringofinhalerswasusedtomeasuremedicationuse.Theprimaryout
